Critiquing: The Institute of Medicine report on cancer care: Is the system “in crisis”?

[1] – 9/19/2013 – “Americans love to fight, traditionally”

“All real Americans love the sting and clash of battle…When you, here, everyone of you, were kids, you all admired the champion marble player, the fastest runner, the toughest boxer, the big league ball players, and the All-American football players”

“Americans love a winner”

“Americans will not tolerate a loser”

– General George S. Patton, Jr., June.5, 1944

The above might as well be Greek to Dr. David H. Gorski a/k/a “Orac”

He’s the epitome of the word “loser”

Indeed, “Orac” described his work-place nemesis as “user hostile”

After 5 years, he still didn’t fully understand much of it, and he claims he’s not exactly computer illiterate

Gorski is that “guy” who couldn’t even find Burzynski’s publication:

[2] – 1997 – Burzynski. S.R. Antineoplastons. oncogenes and cancer

[3] – “Orac” batted the big “O” when he tried to find “the scientific rationale to expect that” antineoplastons “might have antitumor activity”

[4] – Gorski was geniusless when it came to finding “which genes are targeted by antineoplastons,“ proving that he really does NOT know Burzynski’s personalized gene-targeted therapy

In fairness, I will point out that he hasn’t put the time in to learn all the ins and outs of the system …

He pontidefecates about phase II clinical trials when his name isn’t even on a phase 2 trial, too

[5] – 9/19/2013 – He’s the “guy” who’s “mystified” as to how Stanislaw Burzynski “has managed to keep practicing for 36 years after he first began treating patients with an unapproved (not ordinary) chemotherapeutic drug (the concoction of peptides purportedly isolated from blood and urine that Burzynski dubbed “antineoplastons” because of their alleged ability to inhibit the growth of cancer)”

This is not an issue unique to Gorski; I’ve discussed other cases like this, such as Bobby Blaskiewicz, who used his man-crush relationship with Gorski to appear on the Skeptic Canary Show; Davey James, who was only recently stripped of his license to practice in several states of mind; Adam Jacobs, who went so far as to use his business influence to alter his Dianthus Mediclueless web-site in London to be more hack friendly, and an interventist who administered twerkpidity to posers who didn’t have common sense and defrauded minions for tens of millions of minutia

It’s a general problem

However, as far as doctors who should have been shut down a long time ago, “Orac” takes the cake

[6] – He has NOT yet figured out that Burzynski learned from the best

[7] – Who could do it better than someone like Dr. Michael A. Friedman, Associate Director, Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment (DCT), National Cancer Institute (NCI), Department of Health & Human Services (HHS), Public Health Service, National Institutes of Health (NIH) who Burzynski had to deal with:

“This is, as you point out, a most serious matter, and I was hoping that you could allay my concerns by showing me where they are unfounded

“However, your letter conspicuously fails to address them

“You also make reference to “numerous factual misstatements” but fail to identify any of them, much less provide documentation to show they are false”

Pg. 2

“I am glad that you plan to “thoroughly examine the accusations” I have made”

“I also eagerly await a substantiative response to the points raised in my letter of 4/20/1995”

20130920-220216.jpg

20130920-220507.jpg
After all, can we really take a person seriously, who claimed:
——————————————————————
[8] – 11/2/2012 – “Personally, having pored over Burzynski’s publications … “
——————————————————————
[9] – 5/8/2013 – “I’ve searched Burzynski’s publications … “
——————————————————————
[10] – 6/5/2013 – “ … I do know cancer science”
——————————————————————
Uhhhhhhh … yeah

But do you really know Burzynski’s cancer science when you did NOT even know:

“which genes are targeted by antineoplastons“?

Has “GOraCON” (“Orac” + @Gorskon) even read these ?
——————————————————————
[11] – 10/2003 – Waldbillig R, Burzynski SR. Mechanism of action, uptake, and gene array studies on the antineoplastic agent phenylacetylglutamine (PG) in human glioma cells U-87. Neuro-Oncology. 2003; 5: 309

Volume 5 Issue 4 October 2003

(genes CD38, OASL, and TCF8)
——————————————————————
[12] – 10/2007 – Patil, S., Burzynski, S.R., Mrowczynski, E., Grela, K. Phenylacetylglutamine (PG) and phenylacetate (PN) interact additively to produce detachment-induced apoptosis/anoikis in glioblastoma cells. Neuro-Oncology 2007; 9:482

Volume 9 Issue 4 October 2007

We have conducted a total human gene array screen using the Affymetrix Human Genome plus 2.0 oligonucleotide arrays, for genes regulated by PG and a combination of PG and PN

gene TXNIP was up-regulated almost 5-fold with PG, and almost 120-fold using a combination of PG and PN

genes that are significantly up-regulated are CLDND1, ATF3, CASP5, TP53, TRIB3, and UNC5B

Genes that were down-regulated include AKT2, ASPM, CDCA8

(caspase 5, p53, netrin receptor) and AKT pathway (AKT2, TRB3)
——————————————————————
[13] – 10/2008 – Patil, S., Burzynski, S., Chittur, S., Mrowczynski, E., Grela, K. Antineoplaston AS2-1 affects cell cycle checkpoints, leading to apoptosis in human glioblastoma cells. Neuro-Oncology 2008; 10:786

Volume 10 Issue 5 October 2008

Affymetrix Human Genome

CDCs 25A and 25B, cyclins D3 and E, and CDKs 3, 4, and 6

ORC1L and CDC6

MCMs 2, 3, 4, 5, 6, and 7, and CDC7

cyclins A, B1, and B2, polykinase 1, and CDKs 1 and 2

MAD2L1, BUB1 and CDC20

p21, p53, and GADD45A

p21/CDKN1A, and PPM1A

Based on pathway analysis, it was observed that anti-neoplastons affected the expression of more than 40 genes instrumental in the cell cycle in GBM cells
——————————————————————
[14] – 12/2008 – Patil, S., Burzynski, S., Chittur, S., Mrowczynski, E., Grela, K. The ingredients of antineoplaston AS2-1 down-regulate glycolysis pathways in glioblastoma cells. Neuro-Oncology 2008; 10:1148

Volume 10 Issue 6 December 2008

In 2004 the FDA granted orphan drug designation for antineoplastons A10 and AS2-1 for the treatment of brainstem glioma

12 FDA-supervised phase II clinical trials have confirmed anti-tumor efficacy in several types of brain tumors

A total human gene array screen using the Affymetrix Human Genome

The expression of mRNA for vitamin D3 up-regulated protein 1 (VDUP1) was found to be over 100 fold higher for cells treated with PG and PN

succinate dehydrogenase C (SDHC), fumarate hydrogenase (FH), succinate-CoA ligase 1 and 2 (SUCLG1and 2), and aconitase 2 (ACO2)
——————————————————————
[15] – 11/2010 – Patil S, Burzynski SR, Mrowczynski E, Grela K. Targeting MicroRNAs in Glioma Cells with Antineoplastons. Neuro-Oncology 2010; 12, iv10

Volume 12 Supplement 4 November 2010

This study was done using the Dharmacon mRNA profiling array (Thermo Fisher Scientific)

mRNAs 125a-5p and 125a-3p

mRNAs 125a-5p has recently been shown to be regulated by the epidermal growth factor receptor and to function as a tumor suppressor in lung cancer

It has also been shown that the over-expression of mRNA 125a or mRNA 125b caused reduced migration and invasion of SKBR3 breast cancer cells

Using the total human microarray screen (Affymetrix)

AKT2
——————————————————————
[16] – 6/2012 – Sonali, S. Patil, Stanislaw R. Burzynski, Emilia Mrowczynski, Krzysztof Grela, Sridar V. Chittur. Phenylacetylglutaminate and Phenylacetate in combination Upregulate VDUP1, cause cell cycle blockade and Apoptosis in U87 Glioblastoma cells. Journal of Cancer Therapy 2012;3:192-200
——————————————————————
[17] – 9/2012 – Patil, S., Burzynski S.R., Mrowczynski, E., Grela, K. P.003. Phenylacetylglutaminate in combination with Phenylbutyrate effectively inhibits growth of brain tumor cell In Vitro. Neuro-Oncology 2012;14(Suppl. 3):iii16

Volume 14 Supplement 3 September 2012

The FDA granted Orphan Drug designation for Antineoplastons A10 and AS2-1 for the treatment of gliomas, in 2009

12 FDA-supervised Phase II clinical trials have confirmed anti-tumor efficacy in several types of brain tumor

AKT2

PG is not toxic to normal cells whereas PB has dose-limiting neuro-cortical toxicity
——————————————————————
Cancer care: Is the system “in crisis” ?

The Institute of Medicine, just in case you’re like “Orac” and have NOT yet figured it out, “the system” has been “in crisis” since the Gubment “forgot” who they are here to serve

[18] – Gorsi, maybe you can explain to The Institute of Medicine why the Cancer care system is “in crisis” because M.D.’s with Ph.D’s who hold positions “at an NCI-designated comprehensive cancer center,”are responsible for massive fact-checking #FAILS

What did you do, Gorski ?

Phone It in again ?
======================================
REFERENCES:
======================================
[1] – 9/19/2013 – The Institute of Medicine report on cancer care: Is the system “in crisis” ?
——————————————————————
http://scienceblogs.com/insolence/2013/09/19/the-institute-of-medicine-report-on-cancer-care-is-the-system-in-crisis/
======================================
[2] – 1997 – Critiquing: Stanislaw Burzynski: On the arrogance of ignorance about cancer and targeted therapies:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/07/26/x/
======================================
[3] – Critiquing: Dr. David H. “Orac” Gorski and The Skeptics™
http://www.scienceblogs.com/Insolence
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/08/08/critiquing-dr-david-h-orac-gorski-and-the-skeptics/
======================================
[4] – Critiquing: Dr. David H. “Orac” Gorski, M.D., Ph.D, L.I.A.R.:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/08/07/critiquing-dr-david-h-orac-gorski-m-d-ph-d-l-i-a-r/
======================================
[5] – 9/19/2013 – Another case of the failure of physician regulation endangering patients
——————————————————————
http://scienceblogs.com/insolence/2013/09/19/another-case-of-the-failure-of-physician-regulation-endangering-patients/
======================================
[6] – Critiquing: Dr. Michael A. Friedman, Dr. Mario Sznol, Robert B. Lanman, Memorial Sloan-Kettering Cancer Center, Mayo Clinic, Department of Health & Human Services (HHS), Public Health Service, Quality Assurance and Compliance Section, Regulatory Affairs Branch (RAB), Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment (DCT), National Cancer Center (NCI) at the National Institutes of Health (NIH), Stanislaw Burzynski: On the arrogance of ignorance about cancer and targeted therapies:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/08/critiquing-stanislaw-burzynski-on-the-arrogance-of-ignorance-about-cancer-and-targeted-therapies/
======================================
DID Dr. Michael A. Friedman FIB?:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/did-dr-michael-a-friedman-fib/
======================================
Dr. Michael A. Friedman, DATA ?:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/19/dr-michael-a-friedman-data/
======================================
Critiquing: National Cancer Institute (NCI) at the National Institutes of Health (NIH) CancerNet “fact sheet”:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/19/critiquing-national-cancer-institute-nci-at-the-national-institutes-of-health-nih-cancernet/
======================================
[8] – 11/.2/2012
——————————————————————
http://scienceblogs.com/insolence/2012/11/02/stanislaw-burzynski-fails-to-save-another-patient/
======================================
[9] – 5/8/2013
——————————————————————
http://scienceblogs.com/insolence/2013/05/08/eric-merola-and-stanislaw-burzynskis-secret-weapon-against-the-skeptics-fabio-lanzoni-part-2/
======================================
[10] – 6/5/2013
——————————————————————
http://scienceblogs.com/insolence/2013/06/05/odds-and-ends-about-burzynski-clinic/
======================================
[11] – 10/2003
——————————————————————
http://www.burzynskiclinic.com/images/stories/Publications/971.pdf
======================================
[12] – 10/2007
——————————————————————
http://www.burzynskiclinic.com/images/stories/Publications/5169.pdf
======================================
[13] – 2008
——————————————————————
http://www.burzynskiclinic.com/images/stories/Publications/7854.pdf
======================================
[14] – 2008
——————————————————————
http://www.burzynskiclinic.com/images/stories/Publications/7897.pdf
======================================
[15] – 11/2010
——————————————————————
http://www.burzynskiclinic.com/images/stories/Publications/8636.pdf
======================================
[16] – 6/2012
——————————————————————
http://www.burzynskiclinic.com/images/stories/Publications/9219.pdf
——————————————————————
Journal of Cancer Therapy, 2012, 3, 192-200
doi:10.4236/jct.2012.33028 Published Online June 2012
5. Acknowledgements
This study was supported by and carried out at the Burzynski research Institute (BRI), Houston TX, USA. The Microarray assay was supported by BRI and carried out at Center for Functional Genomics, University of Albany, NY, USA
======================================
[17] – 9/2012
——————————————————————
http://www.burzynskiclinic.com/images/stories/Publications/9291.pdf
======================================
http://www.burzynskiclinic.com/scientific-publications.html
======================================
[18] – Wayne State University, Detroit, Michigan, quickly realized that David H. Gorski, MD, PhD, FACS is NOT doing something wrong when he LIES about Burzynski:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/08/27/wayne-state-university-detroit-michigan-quickly-realized-that-david-h-gorski-md-phd-facs-is-not-doing-something-wrong-when-he-lies-about-burzynski/
======================================

Advertisements

Critiquing: Dr. David H. “Orac” Gorski, M.D., Ph.D, L.I.A.R.

L.I.A.R.

Lacking
Integrity
And
Respect

Respect is EARNED

Dr. David H. “Orac” Gorski has NOT earned respect

Neither does he deserve it

6/4/2013 Gorski made an amazing admission:
======================================
http://scienceblogs.com/insolence/2013/06/04/stanislaw-burzynski-versus-the-bbc/
======================================
“Dr. Elloise Garside, a research scientists, echoes a lot of the questions I have, such as”

“how Burzynski never explains which genes are targeted by antineoplastons … “
——————————————————————
Gorski has claimed:
======================================
6/7/2013 “Unlike Mr. Merola, I am indeed very concerned with getting my facts correct”
——————————————————————
http://scienceblogs.com/insolence/2013/06/07/i-want-my-anp/
======================================
6/5/2013 “ … I do know cancer science”
——————————————————————
http://scienceblogs.com/insolence/2013/06/05/odds-and-ends-about-burzynski-clinic/
======================================
11/2/2012 “Personally, having pored over Burzynski’s publications … “
——————————————————————
http://scienceblogs.com/insolence/2012/11/02/stanislaw-burzynski-fails-to-save-another-patient/
======================================
5/8/2013 “I’ve searched Burzynski’s publications … “
——————————————————————
http://scienceblogs.com/insolence/2013/05/08/eric-merola-and-stanislaw-burzynskis-secret-weapon-against-the-skeptics-fabio-lanzoni-part-2/
======================================
7/22/2013 I published the below article on my blog:
======================================
Critiquing: In which Orac does Stanislaw Burzynski propagandist Eric Merola a favor…:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/07/22/critiquing-in-which-orac-does-stanislaw-burzynski-propagandist-eric-merola-a-favor/
======================================
“… because Gorski and others do NOT seem to understand how antineoplastons (ANP) A10 (Atengenal) and AS2-1 (Astugenal) work, I provide the relevant Burzynski publications and page #’s for them to review:
——————————————————————
Gorski, here’s

” … how Burzynski never explains which genes are targeted by antineoplastons … “
======================================
[1] Pg. 98
——————————————————————
ras oncogenes
tumor suppressor gene p53
ras oncogene protein p21ras
p21 gene

======================================
[2] Pg. 47
——————————————————————
oncogenes
tumor suppressor genes

——————————————————————
Pg. 48
——————————————————————
gene p53
WRN gene

——————————————————————
Mechanism of Action of Antineoplaston
——————————————————————
tumor suppressor genes
oncogenes
p21 protein
p53 gene

——————————————————————
Pg. 49
——————————————————————
tumor suppressor gene p53
tumor suppressor gene p21

======================================
[3] Pg. 257
——————————————————————
tumor suppressor genes
oncogenes

——————————————————————
Pg. 260 Discussion
——————————————————————
oncogene AKT2
oncogene RAS
oncogene MYCC
tumor suppressor p53
tumor suppressor p21
tumor suppressor PTEN
tumor suppressor INI1

======================================
[4] Pg. 385
——————————————————————
AKT2 pathway
TGFB1 pathway
RAS
TP53
p21

======================================
[5] Pg. 386
——————————————————————
RAS pathway
AKT2 pathway
TGFB1 pathway
p53 tumor suppressor gene
p21 tumor suppressor gene

======================================
[6] Pg. 323 Discussion
——————————————————————
TP53 gene
——————————————————————
Pgs. 323-324
——————————————————————
RAS oncogene
TP53 tumor suppressor gene
p21 tumor suppressor gene
NF1 tumor suppressor gene
p21 RAS protein
RNAi
dsRNA
siRNA
RAS oncogene pathway (GF-RTK-RAS)
oncogenes
oncogene AKT2

======================================
[7] Pg. 173 Discussion
——————————————————————
proto-oncogene MYCC, ERBB2
——————————————————————
Pg. 174
——————————————————————
sonic hedgehog (SHH) receptor patched (PTCH)
MYCC
MYC-MAX dimers
G1-S
gene CCD2 (encoding cyclin D2)
gene CDK4 (which encodes cyclin dependent kinase 4)
KIP1
(or p27)
CUL-1
CKS
MYC
cyclin E-CDK2
INK4B
(or p15)
p21
cyclin E/CDK2
MIZ1 (MYC-interacting zinc finger protein 1)
CDKN1A
CDKN2B
MAD protein
MEFD2D (MADS box transcription enhancer factor
17p
tumor-suppressor gene HIC-1 (hypermethylated in cancer-1)
RAS/MAPK
RAS pathway
RAS protein
AKT2
BCL2
BCL-X
BAX

——————————————————————
Pgs. 175-176 Charts
======================================
[8] Pg. 40
——————————————————————
RAS
AKT
TP53
PTEN
INI1
p21
MYCC
apoptosis pathway
DNA
p21 protein
RAS oncogene
INI1 protein
BCL-X

——————————————————————
Pg. 41 Targeted Therapy with Antineoplastons chart
——————————————————————
protein p21
RAS oncogene
RAS
BCL-2
tumor suppressor gene TP53
tumor suppressor gene p21
DNA
oncogene AKT2
oncogene MYCC
tumor suppressor gene PTEN
tumor suppressor gene MAD
INI1 protein
BCL-X protein

——————————————————————
Pg. 46 Discussion / Conclusion
——————————————————————
AKT/PTEN
RAS
p53
p21
MYCC
apoptosis pathways

======================================
[9] Pg. 384 E. Multitargeted therapy
——————————————————————
RAS pathway
AKT2 pathway
TP53 pathway
PTEN
INI1
p21 pathway
MYCC
apoptosis pathways
TGFB1 pathway
MAD

======================================
[10] Pg. 1068
——————————————————————
AKT2 pathway
MYCC pathway
TGFB1
PTEN tumor suppressor gene
MAD tumor suppressor gene
RANBP1
INI protein
RAS pathway
BCL2 pathway
tumor suppressor TP53
tumor suppressor p21

======================================
[11] Pg. 923
——————————————————————
AKT pathway
RAS pathway
TP53 pathway
p21 pathway
PTEN pathway

======================================
Burzynski, Hideaki Tsuda (Japan), and the p53 gene:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/03/04/burzynski-hitoshi-tsuda-japan-and-the-p53-gene/
� � � � � � � � � � � � � � � �
References:
� � � � � � � � � � � � � � � �
http://www.burzynskiclinic.com/scientific-publications.html
======================================
[1] 2003
——————————————————————
Interim Reports on Clinial Trials
16. 2003 (BT-11)
Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report
DRUGS IN R&D
——————————————————————
http://www.ncbi.nlm.nih.gov/pubmed/12718563
——————————————————————
Drugs in R and D
——————————————————————
http://www.ncbi.nlm.nih.gov/m/pubmed/12718563
——————————————————————
(Drugs in Research and Development)
——————————————————————
http://www.burzynskiclinic.com/images/stories/Publications/960.pdf
——————————————————————
Drugs R D. 2003;4(2):91-101
Drugs in R&D 2003;4:91-101
======================================
[2] 3/2004
——————————————————————
Review Articles on Clinical Trials:
1. 3/2004
The Present State of Antineoplaston Research
——————————————————————
http://www.burzynskiclinic.com/images/stories/Publications/994.pdf
——————————————————————
Integrative Cancer Therapies 2004;3:47-58
Volume 3, No. 1, March 2004
DOI: 10.1177/1534735-403261964
Volume 3 Number 1 March 2004
======================================
[3] 9/2004
——————————————————————
Case Reports:
4. 9/2004 (Special Exception (SE) to BT-11 Study (ST))
Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme
——————————————————————
http://www.burzynskiclinic.com/images/stories/Publications/1145.pdf
——————————————————————
Integrative Cancer Therapies 2004;3:257-261
Volume 3, Number 3 September 2004
DOI: 10.1177/1534735404267748
======================================
[4] 10/2004
——————————————————————
Interim Reports on Clinial Trials:
2. 10/2004
Phase II study of Antineoplastons A10 and AS2-1 (ANP) in recurrent glioblastoma multiforme
——————————————————————
http://www.burzynskiclinic.com/images/stories/Publications/1218.pdf
——————————————————————
Neuro-Oncology. 2004; 6: 384
Volume 6 Issue 4 October 2004
Abstracts from the Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004
======================================
[5] 10/2004
——————————————————————
Interim Reports on Clinial Trials:
3. 10/2004 (Study (ST) and Special Exception (SE))
Long-term survivals in phase II studies of Antineoplastons A10 and AS2-1 (ANP) in patients with diffuse intrinsic brain stem glioma
——————————————————————
http://www.burzynskiclinic.com/images/stories/Publications/1219.pdf
——————————————————————
Neuro-Oncology. 2004; 6: 386
Volume 6 Issue 4 October 2004
======================================
[6] 2004
——————————————————————
Interim Reports on Clinial Trials:
17. 2004 (BT-13 and BT-23)
Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma :
a preliminary report
DRUGS IN R&D
——————————————————————
http://www.ncbi.nlm.nih.gov/pubmed/15563234
——————————————————————
Drugs in R and D
——————————————————————
http://www.ncbi.nlm.nih.gov/m/pubmed/15563234
——————————————————————
(Drugs in Research and Development)
——————————————————————
http://www.burzynskiclinic.com/images/stories/Publications/1194.pdf
——————————————————————
Drugs R D. 2004;5(6):315-26
Drugs R&D 2004;5(6):315-326.
======================================
[7] 6/2005
——————————————————————
Interim Reports on Clinial Trials:
18. 6/2005 (CAN-01 and BT-12)
Burzynski, S.R., Weaver, R.A., Janicki, T., Szymkowski, B., Jurida, G., Khan, M., Dolgopolov, V.
Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with Antineoplastons A10 and AS2-1
——————————————————————
http://www.ncbi.nlm.nih.gov/pubmed/15911929
——————————————————————
Integr Cancer Ther. 2005 Jun;4(2):168-77
——————————————————————
http://www.ncbi.nlm.nih.gov/m/pubmed/15911929
——————————————————————
Integrative Cancer Therapies 2005;4(2):168-177
——————————————————————
http://www.burzynskiclinic.com/images/stories/Publications/1220.pdf
——————————————————————
DOI: 10.1177/1534735405276835
——————————————————————
http://m.ict.sagepub.com/content/4/2/168.long?view=long&pmid=15911929
——————————————————————
Volume 4 Number 2 June 2005
======================================
[8] 3/2006
——————————————————————
Interim Reports on Clinial Trials:
19. 3/2006 (BT-03, BT-11, BT-18, and CAN-01)
Targeted therapy with Antineoplastons A10 and AS2-1 of high grade, recurrent, and progressive brainstem glioma.
——————————————————————
http://www.ncbi.nlm.nih.gov/pubmed/16484713
——————————————————————
Integr Cancer Ther. 2006 Mar;5(1):40-7
——————————————————————
http://www.ncbi.nlm.nih.gov/m/pubmed/16484713
——————————————————————
Integrative Cancer Therapies 2006;5(1):40-47
——————————————————————
http://www.burzynskiclinic.com/images/stories/Publications/5825.pdf
——————————————————————
DOI: 10.1177/1534735405285380
——————————————————————
http://m.ict.sagepub.com/content/5/1/40.long?view=long&pmid=16484713
======================================
[9] 12/2007
——————————————————————
Review Articles on Clinical Trials:
3. 12/2007
Recent clinical trials in diffuse intrinsic brainstem glioma. Cancer Therapy 2007; 5, 379-390.
——————————————————————
http://www.burzynskiclinic.com/images/stories/Publications/5692.pdf
——————————————————————
Review Article
Cancer Therapy Vol 5, 379-390, 2007
——————————————————————
http://www.cancer-therapy.org/CT/v5/B/HTML/42._Burzynski,_379-390.html
——————————————————————
Volume 5 Number 2 December, 2007
======================================
[10] 12/2008
——————————————————————
Interim Reports on Clinical Trials:
12. 12/2008
(BT-8 – PATIENTS WITH ANAPLASTIC ASTROCYTOMA)
(BT-15 – ADULT PATIENTS WITH ANAPLASTIC ASTROCYTOMA)
Phase II study of antineoplastons A10 and AS2-1 infusions (ANP) in patients with recurrent anaplastic astrocytoma
——————————————————————
http://www.burzynskiclinic.com/images/stories/Publications/7898.pdf
——————————————————————
Neuro-Oncology 2008; 10:1067
Volume 10 Issue 6 December 2008
Abstracts for the Eighth Congress of the European Association for Neuro-Oncology (EANO), Sept. 12-14, 2008, Barcelona, Spain
======================================
[11] 12/2009
——————————————————————
Case Reports:
1. 12/2009 (BT-11 Special Exception (SE))
Over a 10-year survival and complete response of a patient with diffuse intrinsic brainstem glioma (DBSG) treated with antineoplastons (ANP).
——————————————————————
http://www.burzynskiclinic.com/images/stories/Publications/8638.pdf
——————————————————————
Neuro-Oncology 2009; 11:923.
Volume 11 Issue 6 December 2009
Abstracts from the Third Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) and the Sixth Meeting of the Asian Society for Neuro-Oncology (ASNO), May 11-14, 2009, Yokohama, Japan
======================================